Epstein-Barr virus (EBV) isolates can be broadly classified as type 1 or type 2 on the basis of allelic polymorphism of the virus-encoded nuclear antigens EBNAs 2, 3a, 3b and 3c, and individually identified based on Mr values of their EBNA proteins (EBNA type). Here we have used this natural heterogeneity amongst isolates to re-examine the question of EBV persistence in vivo, asking in particular whether virus carriage in oropharyngeal epithelium and/or in B lymphoid tissues involves infection with a single or with multiple virus strains. Firstly, 76 healthy virus carriers were classified into serotype groups on the basis of preferential antibody reactivity to type 1 EBNAs (serotype 1) or to type 2 EBNAs (serotype 2); 60 of the 76 donors were serotype 1, four of the 76 donors were serotype 2 and 12 of the 76 donors were anti-EBNA 2, 3a, 3b, 3c antibody-negative and therefore could not be serotyped. Representative donors from each group were then selected for virus isolations from blood (by spontaneous in vitro transformation) and from throat washings (by cord blood cell transformation). All 13 serotype 1 donors tested and six of seven non-serotypeable donors gave a type 1 virus isolate, whereas all four serotype 2 donors and one of the seven non-serotypeable donors gave a type 2 isolate. Multiple transforming virus isolates from any one donor, whether from blood or throat washings, were all of the one strain characteristic of that particular donor; sequential isolations showed retention of the same strain over several years. Finally, throat washing samples from these same donors were examined for amplifiable EBV DNA in the polymerase chain reaction using EBV type-specific oligonucleotide primers and probes derived from the polymorphic EBNA 2 and EBNA 3c loci. The results were consistent with earlier virus isolation studies, each individual donor showing amplification either of type 1 or type 2 sequences. We conclude that multiple EBV infections must occur rarely, if at all, in healthy virus carriers; EBV persistence in vivo is characterized by dominance of a single transforming virus strain.
Introduction
Epstein-Barr virus (EBV), a herpesvirus widespread in human populations, selectively infects two types of target cells, B lymphocytes and stratified squamous epithelia (Nilsson et al., 1971; Sixbey et al., 1984) . The viral interaction with B cells in vivo appears to be largely nonproductive, whether studied in the acute primary phase of EBV infection associated with infectious mononucleosis (IM) or later following establishment of the life-long virus carrier state (Robinson et al., 1980; Yao et al., 1989a) . Interestingly these virus-carrying B cells, nonproductively infected in vivo, are induced into the lytic cycle on explanation in vitro; the mature virions thereby produced go on to infect other B cells co-resident in the culture, giving rise to the 'spontaneous' outgrowth of EBV-transformed lymphoblastoid cell lines (LCLs) (Rickinson & Epstein, 1975) . This phenomenon of spontaneous outgrowth provides the clearest indication of continued EBV infection in the B lymphoid system of asymptomatic virus carriers.
Stratified squamous epithelium appears to be a more permissive target tissue for EBV in vivo. The clearest evidence comes from oral hairy leukoplakia (OHL), an EBV-associated lesion on the lateral borders of the tongue which is seen most frequently in immunosuppressed individuals. Analysis of OHL biopsies has shown complete replication of the virus in the more differentiated outer layers of stratified epithelium (Greenspan et al., 1985) . This accords with the earlier finding of 0001-0189 © 1991 SGM productively infected squamous epithelial cells being shed into the buccal fluid of acute IM patients (Sixbey et al., 1984) . Virions released from such cells would account for the relatively high titres of transforming EBV which are detectable in the throat washings of IM patients (Gerber et al., 1972) . Indeed, low grade EBV replication in pharyngeal epithelium with shedding of transforming virus into buccal fluid appears to be a continued feature of the asymptomatic virus carrier state .
The relationship between this low grade productive infection in epithelium and the persistent non-productive infection of the B cell system is still not fully understood. Originally we suggested that epithelial cells form the true reservoir for EBV persistence in vivo and that virus carriage in the B cell system is maintained only by continued input from B cells newly infected at epithelial sites . However recent studies on patients receiving long-term acyclovir therapy have shown that the number of virus-carrying B cells in the circulating pool is maintained for at least several weeks in the absence of virus replication at permissive sites (Yao et al., 1989a) . This raises the possibility that EBV can establish independent foci of infection in its two different target tissues and that the epithelial compartment, which is assumed to be the primary site of infection, might be colonized by more virus strains than gain access to the lymphoid pool.
In order to pursue this question further, we sought to take advantage of the extreme heterogeneity which exists amongst individual EBV isolates. Two broad families of virus, EBV types 1 and 2, were first distinguished on the basis of genetic polymorphism in the virus-encoded nuclear antigen 2 (EBNA 2) coding sequence (Dambaugh et al., 1984; Adldinger et al., 1985) . Subsequently the allelic polymorphism distinguishing EBV types 1 and 2 has been shown to extend to the EBNA 3a, 3b and 3c coding sequences (Rowe et al., 1989; Sample et al., 1990) . Antibody responses to these polymorphic EBNA proteins therefore tend to be type-specific whereas antibodies to the more highly conserved EBNA 1 protein are cross-reactive between virus types (Rowe et al., 1989) . In addition to this broad distinction between EBV types 1 and 2, there is also micro-heterogeneity within each virus type; this is most easily detected by variations in the size of the individual EBNA proteins which are apparent after their electrophoretic separation on polyacrylamide gels. The EBNA 1, 2, 3a, 3b and 3c proteins encoded by any one virus isolate display a unique size combination in gels which has been termed the 'EBNA type' of that particular isolate (Gratama et al., 1990) . Sizing of EBNA-LP, the sixth virus-encoded nuclear antigen constitutively expressed in transformed cells (Kieff & Liebowitz, 1990) , is not helpful in this context because even a single virus strain can encode a ladder of EBNA-LP species of different Mr values, each species containing a different number of repeat motifs (Finke et al., 1987) .
Here we have examined the possibility that multiple EBV strains might become established in the epithelial cell or lymphoid cell compartments of healthy virus carriers. To do this we have used three independent approaches, each of which depends upon genetic heterogeneity between EBV types or micro-heterogeneity within each type. These approaches are (i) serotyping of individuals for evidence of type-specific antibody responses, (ii) EBNA typing of EBV strains isolated from such individuals and (iii) DNA amplification of throat washing-derived viral sequences using typespecific primers and probes.
Methods
Donors. The study group was made up of 76 healthy laboratory workers (age range 20 to 55 years) with serological evidence of previous EBV infection. All donors were Caucasian with the exception of two Chinese donors, QY and QX. All but three donors had been EBV antibody-positive for at least 3 years before this study and had no clinical history of IM; the exceptions (HGr, AD and JSh) had each undergone a proven primary infection within the previous 2 years. Blood and throat washing samples were taken on successive occasions from the above donors as already described . Peripheral blood samples provided plasma for serological studies and mononuclear cells for culture work; throat washings provided cell-free virus for culture work and cell pellets for DNA amplification studies. Parallel samples were also taken from known EBV seronegative donors to provide control material for serological, cell culture and DNA amplification assays.
Serotyping. Analysis of serum antibodies to EBNAs 1, 2, 3a, 3b and 3c was conducted by Western blotting on protein extracts from three reference cell lines: (i) the EBV-negative BL40 cell line used as a negative control, (ii) the C2+OBA LCL generated by in vitro transformation of cord blood B cells with a reference type 1 EBV isolate from the OBA-BL cell line and (iii) the C2 + BL16 LCL generated by in vitro transformation of the same cord blood B cells with a reference type 2 EBV isolate from the BL16 cell line . As fully described elsewhere (Rowe et al., 1989) , sets of extracts from 106 cells per reference line were separated on a 7.5% polyacrylamide gel, electroblotted on nitrocellulose, then probed with the test human serum at a 1:100 dilution by overnight exposure at 4 °C. Specifically bound antibody was detected using ~25I-labelled Protein A.
Rescue of transforming EBV isolates. Unfractionated mononuclear (UM) cells isolated from peripheral blood using Ficoll/Hypaque were cultured at 106, 5 x 10 s and l0 s cells per 0.3 ml microtest plate well in complete culture medium [RPMI 163,0 + 2 mM-glutamine + 100 l-tg/ml streptomycin + 100 international units (IU)/ml penicillin + 10% foetal calf serum (FCS)]; cyclosporin A was added to a final concentration of 0.1 ~tg/ml to inhibit T cell-mediated inhibition of B cell outgrowth (Rickinson et al., 1984) . These cultures were maintained with regular refeeding for a period of at least 12 weeks and observed for evidence of 'spontaneous' outgrowth to LCLs.
Throat washings taken in 10 ml PBS were immediately clarified by bench centrifugation and the supernatant fluid was filtered through a 0.45 ~tm filter (Millipore). After filtration, FCS was added to the supernatant fluid to 10% (v/v) and this mixture immediately added to l0 T cord blood UM cells resuscitated from frozen cell stocks for which sensitivity to EBV-induced transformation had already been checked . After 2 h at 37 °C, the cord cells were washed, resuspended in complete culture medium and seeded into 0-3 ml microtest plate wells at 106 cells/well. These cultures were likewise maintained with regular refeeding for a period of at least 12 weeks and observed for evidence of EBV-induced transformation.
In both types of assay, individual culture wells showing evidence of lymphoblastoid cell outgrowth were expanded separately to give separate cell lines. Where a number of replicate culture wells showed outgrowth, care was taken to expand all available wells irrespective of cell growth rate.
EBNA typing. Extracts from 106 cells of each test cell line were separated and electroblotted as above (see Serotyping) and then probed with reference human sera or with monoclonal antibodies (MAbs). In the first instance all lines were probed with a human serum (PB) which contains high titre antibodies to the non-polymorphic EBNA 1 protein, to the EBNA 3a and EBNA-LP proteins of both virus types, and to EBNA 2, EBNA 3b and EBNA 3c proteins encoded by type 1 virus isolates. Further analysis was carried out using either EBNA 1-specific antibodies immunopurified from human serum on a p107 Gly-Ala repeat peptide column (Dillner et al., 1984) , the MAb PE2 reactive against a common epitope on type 1 and type 2 EBNA 2 proteins , or human sera such as AW which is predominantly reactive against the type 2 EBNA 2 protein with little reactivity against other EBNA species.
Virus typing by DNA amplification. Cell pellets obtained from the initial clarification of throat washings by bench centrifugation (see above) were treated to yield high Mr DNA by standard SDS lysis, proteinase K digestion and extraction with phenol (Maniatis et al., 1982) . Nucleic acids were precipitated with ethanol, redissolved in 100 ~tl distilled water and then stored at -20 °C; DNA in 5 ~tl aliquots from this preparation was then amplified in a 100 ktl reaction under conditions already described (Sample et al., 1990) . After 40 cycles of amplification in a DNA Thermal Cycler (Perkin-Elmer) with appropriate primers, amplified products were separated by electrophoresis in 3% agarose gels, then transferred into a Hybond N + membrane (Amersham). The membrane-bound products were hybridized to an appropriate oligonucleotide probe which had been endlabelled with 32p using T4 polynucleotide kinase. DNA amplifications were carried out using sets of oligonucleotide primers and probes selected either from the EBNA 2 type 1 and type 2 coding sequences, or from the EBNA 3c type 1 and type 2 coding sequences (see Results section for details). For amplification of EBNA 2 sequences, replicate 5 Ixl aliquots were amplified using a common 5' primer and one of two type-specific 3' primers; the products were then separately electrophoresed, transferred to membranes and hybridized to the relevant typespecific probe. For amplification of EBNA 3c sequences, one 5 ktl aliquot was amplified using common 5' and 3' primers; aliquots of the product were then separately electrophoresed, transferred to membranes and hybridized to either the type 1-specific or type 2-specific probe. The presence of amplifiable DNA in all throat washing cell extracts was in each case confirmed using primers PC03 and PC04 specific for the human fl-globin gene (Saiki et al., 1985) .
Results

Serotyping of healthy virus carriers
Sera were tested for evidence of type-specific antibody responses against the polymorphic EBNAs by immunoblotting against protein extracts of LCLs (C2 + OBA, C2 + BL16) transformed with a reference type 1 virus isolate (OBA strain) or a reference type 2 isolate (BL16 strain). These particular isolates were selected from a large panel of possible reference strains because they had been found to encode EBNA 1, 2, 3a, 3b and 3c proteins which showed good separation from one another in polyacrylamide gels (Rowe et al., 1989) , thereby facilitating interpretation of the immunoblots. Fig. 1 shows representative results obtained when sera from six test donors (LY, MR, QX, IB, AC, AW) were used to probe extracts of the reference LCLs and of the control EBVnegative BIA0 cell line. To clarify the interpretation of serotyping data, the relevant EBNA reactivities are reproduced in the diagram below each set of tracks.
Donor LY serum showed reactivity against the nonpolymorphic EBNA 1 protein only; note that EBNA 1 appears in these particular immunoblots as a strong upper band and a weaker lower band, the latter representing a breakdown product. Donor LY therefore provides an example of a 'non-serotypeable' donor with no detectable antibodies to any of the polymorphic EBNA proteins. By contrast, donors MR, QX and IB could be classified as serotype 1. Thus MR serum reacted not just with the EBNA 1 of both virus isolates but also showed strong type-specific reactivity against the type 1 EBNA 2 protein. The QX serum was essentially similar to that of MR except that type 1-specific reactivity was seen not just against EBNA 2 but also against the EBNA 3b and EBNA 3c proteins; donor QX also had anti-EBNA 3a reactivity but, as noted in earlier work (Rowe et al., 1989) , responses to EBNA 3a tend to be crossreactive between virus types and are therefore less instructive for serotyping purposes. The IB serum likewise contained cross-reactive anti-EBNA 1 (weak) and anti-EBNA 3a antibodies, and showed type 1-specific reactivity against the EBNA 3b and 3c proteins; here, however, the anti-EBNA 2 response was not completely type-specific, but showed strong recognition of the type 1 protein and weaker recognition of the type 2 protein. Such 'cross-reactivity' of anti-EBNA 2 antibodies was observed in only a minority of serotype 1 donors, and was never stronger than that illustrated in Fig. 1 for serum IB. Fig. 1 also shows representative immunoblotting data from two donors, AC and AW, classified as serotype 2. Donor AC serum has strong anti-EBNA 1 reactivity, an anti-EBNA 2 response preferentially detecting the type 2 protein and also a type 2-specific EBNA 3c reactivity. Donor AW serum has a weak anti-EBNA 1 reactivity but a strong anti-EBNA 2 response, again preferentially detecting the type 2 protein. This illustrates a trend seen both in this work and in earlier studies (Rowe et al., 1989) , namely that sera classified into the serotype 2 group quite often show weak 'cross-reactive' recognition of the type 1 EBNA 2 protein. Sera from a total of 76 healthy virus carriers were analysed in the manner outlined above. Of these, 60 donors (79~o) were classified as serotype 1, four (5~) were classified as serotype 2, and 12 donors (16~) could not be serotyped because they lacked detectable antibodies to any of the polymorphic EBNAs.
Initial virus isolations from serotyped donors
Following the above classification into serotype groups, seven of 12 donors from the 'non-serotypeable' group, 13 of 60 donors from the serotype 1 group and four out of four donors from the serotype 2 group were selected for virus isolation studies. In an initial series of experiments, blood and throat washing samples were taken from each of these 24 donors in an effort to establish (i) a spontaneous cell line from cultured peripheral blood UM cells and (ii) a cord blood cell line transformed with throat washing-derived virus. Virus isolations from one or both sources were made for each of these 24 individuals and the type of isolate was determined by immunoblotting of LCL extracts with selected human sera. Fig. 2 of the donors from whom both a spontaneous peripheral blood-derived LCL and a throat washing virus-derived LCL were available; in this case protein extracts of these cell lines were run alongside extracts of reference lines and then the gel was probed with a human serum PB showing preferential reactivity against the type 1 polymorphic EBNAs. As can be seen from the reference tracks, PB serum identified EBNAs 1, 2, 3a, 3b and 3c in the type 1 virus-transformed LCL X50-7 but only EBNAs 1 and 3a in the type 2 virus-transformed LCL JC5; the specificity of these reactions is made clear by comparison with the background reactivity against the EBV-negative B JAB cell extract. The EBNA protein patterns in cell lines derived from donor CM (nonserotypeable) and from donors HGr and JW (both serotype 1) are diagnostic of type 1 EBV isolates; in contrast the EBNA patterns in cell lines derived from donor CP (serotype 2) and donor AM (non-serotypeable) suggest the presence of type 2 isolates, and this could be confirmed by immunoblotting with a type 2-specific human serum (data not shown). It should be emphasized that the results obtained by immunoblotting with any one polyvalent human serum are rarely sufficient on their own to define an accurate EBNA type. Taking the example of serum PB used in Fig. 2 , in addition to its annotated EBNA reactivities this particular serum also reacts with a 63K band in the spontaneous LCL from donor AM but not in the paired throat washing-derived LCL. In fact, further analysis with other sera clearly identified this 63K band as an unusually large species of EBNA-LP, the virus-encoded nuclear antigen which can vary in size even among cell lines carrying the same virus isolate. The identities of the individual EBNA bands shown for each isolate in Fig. 2 '(and in later figures) are therefore based not only on the gels shown but also on the results from additional gels probed either with MAbs or with other human sera showing selective reactivities against certain of the EBNAs. In this initial analysis of single or paired isolates from individual donors, all 13 individuals analysed from the serotype 1 group yielded type 1 virus isolates whereas all four members of the serotype 2 group yielded type 2 isolates. Of the seven 'non-serotypeable' donors analysed, six gave type 1 isolates and one (donor AM) gave a type 2 isolate. A detailed breakdown of the virus isolation data for all 24 individual donors is presented later as part of Table 1 . Two further features of the results, both illustrated in Fig. 2 , need to be noted. Firstly, each individual analysed carried a unique virus isolate as defined by its unique EBNA type, i.e. by the particular combination of sizes of the virus-encoded EBNA 1, 2, 3a, 3b and 3c proteins. From Fig. 2 , this is best illustrated with reference to the type 1 isolates examined (from donors CM, HGr and JW) since this gel was probed using a human serum with type l-specific reactivities. Secondly, the peripheral blood-derived LCL . EBNA typing of multiple virus isolates (a) from serotype 1 donor IB (throat washing isolates) and (b) from serotype 1 donor AD (peripheral blood isolates). Extracts of multiple independently derived cell lines from these donors, and from the reference cell lines X50-7 (type 1 LCL) and BL40 (EBV-negative), were probed with human serum PB reactive with EBNAs 1, 2, 3a, 3b and 3c (upper panels) and with affinity-purified EBNA l-specific antibodies (lower panels). Note that in the lower panel of (b) Ponceau staining for total protein revealed that the AD Sp LCL 3 track was underloaded relative to the other tracks, thus explaining the weaker EBNA 1 signals. Mr markers are shown on the left of (a) and (b). and the throat washing virus-transformed LCL from any one donor carried the same virus isolate with the same characteristic E B N A type.
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Multiple virus isolations from serotyped donors
In subsequent experiments we sought to derive multiple virus isolates from the peripheral blood and/or throat washings of the same individual donors. Earlier work had shown that type 1 virus isolates transform B cells in vitro more efficiently than type 2 isolates . For this reason, we attempted in these experiments to expand all of the available microtest plate cultures showing evidence of cell growth transformation, irrespective of their rate of expansion, so as not to give preference to those virus isolates yielding faster growing lines.
Multiple virus isolations(two to 60 isolates per donor) were achieved from 17 of the 24 donors from whom single or paired virus isolates had been obtained in the initial work above. In some cases this involved prolonged maintenance of original cultures followed by slow expansion of the cell line, such that several months elapsed between initiation of the culture and the preparation of transformed cell extracts. We nevertheless only ever isolated one transforming virus strain from any one individual; all of the isolates from any one donor gave the same E B N A type as the original isolate derived from that donor in the initial set of experiments. Full details of results from individual donors are presented later as part of Table 1 .
The uniform pattern of results from these virus isolation studies is illustrated in Fig. 3 . Multiple LCLs derived by in vitro transformation of cord blood B lymphocytes using throat washings from donor IB, including some of those LCLs which were the most difficult to establish, all carried a type 1 virus with the same characteristic E B N A type showing clear separation of the E B N A 3a, 3b and 3c proteins and comigration of EBNAs 1 and 2 (Fig. 3a, upper panel) . The uniform size of the E B N A 1 protein in isolates from donor IB is better illustrated in an immunoblot probed with an E B N A 1-specific reagent (Fig. 3a, lower panel) and a similar uniformity of E B N A 2 size was observed on probing with the E B N A 2-specific MAb PE2 (data not shown), (1982, 1986, 1989 ) from four serotype 1 donors. Extracts were probed with the human serum PB reactive with EBNAs 1, 2, 3a, 3b and 3c. Note that this autoradiograph was over-exposed to visualize the EBNA 3 family of proteins as well as EBNAs 1 and 2; lower exposures made it clear that the EBNA 1 and EBNA 2 bands were of constant size in sequential isolates. Mr markers are shown on the right. a different donor, AD. Again each individual line carried the same type 1 virus isolate with its own characteristic EBNA type. In this particular series of isolates, we noted in one LCL (AD spontaneous LCL 3) the presence of an additional band appearing in immunoblots below the usual EBNA 1 band (Fig. 3b, upper panel) . Probing with an EBNA 1-specific reagent confirmed that the additional band was indeed EBNA 1-related (Fig. 3b, lower  panel) . This same phenomenon was also noted in one of the isolates from a second donor, HGr, and again involved the appearance of a second EBNA 1 band with no detectable changes in observed Mr values of the other EBNA proteins.
Sequential virus isolations from selected donors
In the course of earlier studies unpublished work) virus isolations had been made from a panel of 10 healthy virus carriers sampled first in 1982 and then again in 1986. During the present work we established spontaneous peripheral blood-derived and/or throat washing virus-derived LCLs from these same 10 donors, using fresh samples taken in 1989. Of these 10 donors, seven formed part of the present study panel (donors SC, MR, SF, QY, AR, JSw and H G a ; see Table  1 later) whereas the remaining three (donors TH, MP and TR) had been part of the study panel in earlier work .
The results of such sequential virus isolations were quite clear-cut. In each case, the same individual virus isolate was obtained from donor samples taken up to 7 years apart. Representative results are shown in Fig. 4 where extracts of sequentially derived cell lines from four donors have been probed with human serum PB and the autoradiograph was deliberately over-exposed in order to visualize the EBNA 3 family of proteins as well as EBNAs 1 and 2. From the characteristic EBNA typing, it is clear that each of these particular donors carries a unique type 1 EBV isolate which has been stably maintained in vivo over several years.
DNA amplification of throat washing-derived viral sequences from serotyped donors
The final series of experiments was carried out after the virus isolation studies and was based on later throat washing samples taken from 22 of the original panel of 24 study donors. Samples were collected on up to five occasions from each of these individuals and in each case D N A prepared from shed cells in throat washings was subjected to amplification via the polymerase chain reaction using type-specific sets of oligonucleotide primers and probes selected from the EBNA 2-and EBNA 3c-coding sequences. Fig. 5 illustrates the results obtained in one such experiment where aliquots of D N A samples from serotyped donor throat washings (including EBV-seronegative throat washings as a source of control DNA) were amplified and analysed for E B N A 2 type 1 or EBNA 2 type 2 sequences. Following 40 cycles of amplification with a common 5' primer in combination with either a type 1-specific or a type 2-specific 3' primer, the products were separated by agarose gel electrophoresis and hybridized with the appropriate type 1-specific or type 2- t Results with type-specific sequences from EBNA 2-and EBNA 3c-coding sequences were concordant. A dash (-) indicates that no EBV-specific amplified DNA was detectable; throat washings from two donors were not tested (wr).
HGr, and from the non-serotypeable donors CM, DH and SC (Fig. 6, upper panel) , whereas the 246 bp type 2 amplification product was detected only using DNA from the serotype 2 donors AC and CP (Fig. 6, lower  panel) .
Overall we were able to detect specific amplification products from throat washing DNA of 17 of the 22 serotyped donors tested, although not every one of the sequential throat washings obtained from these 17 individuals gave positive results. For those samples which did give positive signals however, the results of EBNA 2-based amplifications and of EBNA 3c-based amplifications were concordant. In each case the amplified sequences were exclusively either of type 1 or of type 2 and were consistent with the virus type isolated from that individual in the in vitro transformation experiments. We never detected amplifiable DNA of both virus types together in the same sample although, in reconstruction experiments, deliberate mixing of DNAs from type 1 and type 2 LCLs in relative ratios ranging from 1000 : 1 to 1 : 1000 showed that each type of sequence remained detectable in the presence of its allele (data not shown). The DNA typing data from throat washing samples is summarized in Table 1 for each of the individuals analysed in the different serotype groups, alongside details of the number and type of transforming virus isolates rescued from these same individuals in the cell culture experiments.
Discussion
The point at issue here is the frequency with which longterm EBV carriage in the lymphoid or epithelial cell compartment of healthy individuals involves the presence of multiple virus strains, in particular the coresidence of type 1 and type 2 virus isolates. Before attempting direct virus isolation, we classified our test donors into serotype groups, based on their pattern of antibody reactivities to the four EBV proteins, EBNAs 2, 3a, 3b and 3c, showing greatest diversity between type 1 and type 2 isolates (Rowe et al., 1989) . Antibodies to these proteins were detectable in the great majority (84%) of healthy virus carriers and, where present, always revealed preferential reactivity in immunoblotting either against the type 1 or type 2 reference LCL (see Fig. 1 ). Therefore only the 16% of virus carriers lacking detectable anti-EBNA 2, 3a, 3b or 3c reactivities were 'non-serotypeable'.
Usually serotyping could be achieved on the basis of anti-EBNA 2 responses alone. Thus in our panel of virus carriers (predominantly Caucasian), 79 % were serotype 1 and most of these individuals recognized the type 1 EBNA 2 protein with little or no reactivity against type 2. Another 5 % of donors were serotype 2 and recognized the type 2 EBNA 2 protein preferentially, although showing weak reactivity against the type 1 protein. We did not find healthy donor sera with strong responses both to type 1 and to type 2 proteins. Instances of weak reactivity against the non-preferred EBNA 2 type represent, we believe, genuine cross-recognition of antigenic epitopes common to both proteins rather than separate antibody responses to co-resident type 1 and type 2 viruses. In donors showing such cross-reactivity (e.g. serotype 1 donor IB, serotype 2 donors AC and AW), the virus isolation data strongly argue against dual infection. Moreover, in the case of donor IB, the EBNA 2 type 1-reactive antibodies could be eluted from a type 1 LCL immunoblot (see Finke et al., 1987) and formally shown to cross-react with the EBNA 2 type 2 protein by probing a type 2 LCL immunoblot (M. Rowe, unpublished results) .
Having determined the distribution of our normal donor population within these three serotype groups, we selected representative donors from each group for virus isolation studies. The initial isolations (Fig. 2) immediately suggested that serotype was predictive of the dominant type of transforming EBV rescuable both from the blood and from the throat of healthy virus carriers. Thus all 13 serotype 1 donors studied gave type 1 virus isolates and all four serotype 2 donors gave type 2 isolates. The distribution of virus isolates among 'nonserotypeable' donors (six type 1, one type 2) was not significantly different from that which we would expect from the healthy virus-carrying population as a whole. Lack of detectable antibody responses to EBNAs 2, 3a, 3b and 3c is therefore not indicative of infection with any particular virus type.
These paired blood-and throat washing-derived cell lines consistently yielded isolates which were identical by EBNA typing (see Fig. 2 ). This result confirmed our earlier findings on IM patients (Yao et al., 1989b) , on herpes zoster patients (Yao et al., 1989a) and on other healthy seropositive donors (Q. Y. Yao, unpublished results) ; in all we have now rescued identical pairs of blood and throat washing isolates from more than 50 infected individuals. Assuming that EBV detectable in throat washings is indeed derived from productively infected epithelial tissues lining the oropharynx (Sixbey et al., 1984) and not from rare infiltrating B cells, this strongly suggests that the same transforming strain of EBV is dominant both in the B cell compartment and in the epithelial cell compartment of healthy virus carriers. Our next objective was to derive multiple EBV isolates from both sites by re-sampling the same panel of 24 selected donors. In all we were able to establish and characterize 121 peripheral blood isolates from 16 of these donors, and 108 throat washing isolates from seven donors. Each isolate was derived from a single microtest well culture and considerable efforts were made to expand as many positive cultures as possible, irrespective of cell growth rate, so as not to introduce bias in favour of EBV isolates yielding faster growing cell lines. The pattern of results remained the same (see Fig. 3 ), all isolates from any one individual showing the same EBNA type. The only possible exceptions were one of 16 isolates from donor AD (Fig. 3) and one of 20 isolates from donor HGr, both of which showed an additional EBNA 1 band of lower Mr. Although these may simply have been breakdown products, breakdown on this scale was not observed in any of the other parallel LCL extracts. Another possible explanation in such cases is that a recombinant virus has been generated during in vivo replication of the resident EBV strain by a recombination event involving the internal repeats within the EBNA 1-coding sequence (Heller et al., 1982) . Whatever the real basis of these multiple EBNA 1 signals, the fact that such multiplicity was not observed for the other EBNA proteins in these same extracts argues against the presence of two independent virus strains.
Despite our efforts to avoid bias in the virus isolation assay, it was not possible to expand every focus of lymphoblastoid growth to the point at which sufficient virus-transformed cells were available for EBNA typing. Thus one could argue that individuals yielding a dominant type 1 isolate may actually carry a co-resident type 2 virus in vivo but that this would remain undetected in vitro because of its poorer transforming efficiency. We would counter this argument by two observations. Firstly, in preliminary reconstruction experiments (unpublished results), we exposed cord blood ceils to virus mixtures containing 100 transforming units/ml of the type 1 EBV B95.8 strain and 1 to 10 transforming units/ml of the type 2 AG876 strain and confirmed that we could indeed detect type 2-transformed cells among the expanded microtest well foci. Secondly, our culture system was sufficiently sensitive to rescue a total of 19 type 2 isolates from the five of 24 donors in the test panel who were clearly type 2 virus carriers. It is noteworthy that both in this study of healthy donors in Britain, and in our earlier study of healthy donors in Kenya where type 2 strains are more prevalent, multiple isolations never produced evidence of dual infection; individual donors always yielded either a type 1 or a type 2 virus isolate. We have now followed three of the type 2 virus carriers identified in the present work for more than 2 years. Significantly these young individuals, all aged between 20 and 30 years, have stably retained their resident type 2 isolate despite the fact that type 1 virus strains are so prevalent in the community. The overall evidence therefore suggests that dual infection with type I and type 2 transforming virus strains must occur very rarely if ever in healthy virus carriers.
The apparent resistance of virus carriers to superinfection with a second virus strain is brought home even more forcibly by the evidence from EBNA typing. Firstly, multiple isolates from any one individual are not only of the same virus type but also of the same virus strain (Fig. 3) ; secondly the resident EBV strain in any one individual is stably retained over several years (Fig.  4) , despite the extreme heterogeneity of strains which are circulating in the community as a whole (see heterogeneity of EBNA types between different donors in Fig. 2 to  4) . If multiple infections were the norm, we would anticipate that many individuals in our test panel would be carrying more than one type 1 virus; furthermore this multiplicity should be reflected in the virus isolation assays, since there should be no inherent difference in detectability amongst type 1 strains. In fact, such multiplicity was never observed despite the large number of isolates examined.
An independent approach to the analysis of EBV carriage has been developed by Sixbey et al. (1989) using DNA amplification by polymerase chain reaction for EBV DNA sequences in the EBNA 2-coding region which are polymorphic between type 1 and type 2 isolates. DNA amplification has the advantage of extreme sensitivity and the potential to detect nontransforming, replication-competent EBV strains which arise during virus replication in vivo and which may be transmissible (Patton et al., 1990; Sixbey et al., 1991) . We chose to analyse our donors by DNA amplification using primer-probe combinations from two separate polymorphic loci, in the EBNA 2 and EBNA 3c gene sequences respectively. These combinations, developed and validated on many different virus strains in the course of earlier work (Sample et al., 1990) , should allow detection and typing of all resident transforming EBV strains and also of non-transforming deletion mutants, even where EBNA 2 gene deletion has occurred (Patton et al., 1990) . We also chose to amplify total DNA from shed cells in throat washings, rather than DNA from cell-free filtrates as used by Sixbey and colleagues, because the latter method gave a detectable signal from only a minority (22 ~) of healthy virus carriers (Sixbey et al., 1989) . In the present study almost all the donors analysed gave positive amplifications either of type 1 or of type 2 sequences, but not of both. In each case the type of amplifiable sequence, both from the EBNA 2 and from the EBNA 3c loci, matched the type of virus isolate rescued from that same individual in the in vitro transformation assays.
We must stress that our findings are based upon an indepth study of a relatively small panel of 24 healthy virus carriers whereas Sixbey et al. (1989) studied a much larger panel of 157 healthy donors by DNA amplification only and found just three individuals with evidence of both virus types in the oropharynx. The overall pattern of results in the two studies is therefore quite similar, showing the presence of just one virus type in most healthy individuals, although the prevalence of type 2 virus infection appears to be higher in the adult population studied by Sixbey in the southern United States than in our British donors. In the present work, we have confined our attention to EBV carriage in the healthy adult population. It may well be that the situation can change quite dramatically in immunosuppressed individuals where the DNA amplification data of Sixbey et al. (1989) , and also evidence from derived cell lines analysed by restriction fragment length polymorphism and by Southern blotting with typespecific probes (Katz et al., 1988; Sculley et al., 1990 ), indicate a much higher incidence of dual infection. It will be important to determine whether these infections occur by direct blood transfer/transplantation (Gratama et al., 1988; Cen et al., 1991) or whether immunologically compromised individuals actually become more susceptible to sequential infections by the natural oropharyngeal route.
